Immunomedics (IMMU) Receives Buy Rating from Cowen

Immunomedics (IMMU) Receives Buy Rating from Cowen


's stock had its "buy" rating reaffirmed by Cowen in a research note issued to investors on Friday. They currently have a $30.00 target price on the biopharmaceutical company's stock.



from Biotech News
Share:

Комментариев нет:

Отправить комментарий

Pharmacy News Digest

Архив блога